A Study of the Value of p53, HER2, and Bcl-2 in the Prediction of Response to Doxorubicin and Paclitaxel as Single Agents in Metastatic Breast Cancer: A Companion Study to EORTC 10923

This publication has 21 references indexed in Scilit:

• Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over
  Journal of Clinical Oncology, 2000
• erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer
  JNCI Journal of the National Cancer Institute, 1998
• No significant predictive value of c- erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer
  International Journal of Cancer, 1998
• p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
  Journal of Clinical Oncology, 1998
• Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer
  British Journal of Cancer, 1997
• Expression of drug resistance proteins in breast cancer, in relation to chemotherapy
  International Journal of Cancer, 1997
• Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
  Nature Medicine, 1996
• The hunt for Ras targets
  Nature, 1994
• The regulation of p53 function: Steiner award lecture
  International Journal of Cancer, 1994
• p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
  Cell, 1993